Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 12/20 | 0.50 |
| ▸ | PARP1 | P09874 | 2/20 | 0.44 |
| ▸ | IKBKB | O14920 | 2/20 | 0.43 |
| ▸ | CHUK | O15111 | 2/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1016136 | 1.00 | HTR6 (0.50) | HTR6PARP1IKBKBCHUKCSF1R | |
| SCHEMBL1014350 | 0.83 | HTR6 (0.54) | HTR6HTR2CHTR2B | |
| SCHEMBL1014349 | 0.83 | HTR6 (0.54) | HTR6HTR2CHTR2B | |
| SCHEMBL1014570 | 0.81 | HTR6 (0.53) | HTR6HTR2CHTR2B | |
| SCHEMBL1013030 | 0.80 | HTR6 (0.54) | HTR6HTR2CHTR2B | |
| SCHEMBL1015178 | 0.80 | HTR6 (0.54) | HTR6HTR2CHTR2B | |
| SCHEMBL1013763 | 0.80 | HTR6 (0.51) | HTR6HTR2CHTR2B | |
| SCHEMBL1013762 | 0.80 | HTR6 (0.51) | HTR6HTR2CHTR2B | |
| SCHEMBL5330092 | 0.78 | PARP1 (0.54) | PARP1IKBKBCHUKCSF1RBTK | |
| SCHEMBL14869717 | 0.78 | PARP1 (0.54) | PARP1IKBKBCHUKCSF1RBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081890-B1 | ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-7776910-B2 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776910-B2 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC (US) | 2010-08-17 | — | — | US | disclosed |
| US-20080167361-A1 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC | 2008-07-10 | — | — | US | disclosed |
| US-20080167361-A1 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167361-A1 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | HTR6, HTR1B, HTR1F | HTR6 1/4885PARP1 839/4885IKBKB 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.